Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | ANPEP | P15144 | 2/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682451 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL19744398 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL19744399 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29260191 | 1.00 | MMP2 (0.54) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL16171925 | 0.87 | MMP2 (0.71) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL28539537 | 0.85 | MMP2 (0.42) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29162169 | 0.85 | MMP2 (0.42) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL25368206 | 0.83 | MMP2 (0.41) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29930727 | 0.83 | MMP2 (0.41) | MMP2ANPEPDPP7DPP8DPP9 | |
| SCHEMBL29930529 | 0.83 | MMP2 (0.41) | MMP2ANPEPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | MMP2 4573/4885ANPEP 4168/4885DPP7 2875/4885 |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | MMP2 4573/4885ANPEP 4168/4885DPP7 2875/4885 |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | MMP2 4573/4885ANPEP 4168/4885DPP7 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.